The Columbia University Irving Medical Center (CUIMC) Diversity in Clinical Trials Training Program: A novel approach to improving inclusivity and generalizability of clinical research

Alexis Pissey Keo, MPH, Edward Bentlyewski, MSN, NP, Bori Lesser-Lee, Moshe Kelsen, MBA, Andrew Lassman, MS, MD, FAAN, Mary Welch, MD, MS

BACKGROUND

- While clinical trials are essential to improving health outcomes, lack of diversity among participants limits generalizability of research and perpetuates disparities
- New FDA requirements aim to align study demographics with overall population, but other approaches are needed
- Future trialists need explicit training in recognizing and mitigating barriers to access at every step of a clinical trial, from design to publication
- Under the Columbia/Pfizer Initiative for Clinical Trial Diversity, the creation of the Diversity in Clinical Trials Training aims to address these needs

GOALS

This program aims to:

- Provide foundational training on clinical trial design and execution while integrating concepts of health equity
- Explores barriers to accrual from underrepresented populations
- Address barriers through thoughtful study design, community partnerships, and industry collaboration
- Prepare participants to lead clinical research that is high quality, inclusive, and equitable

SOLUTIONS/METHODS

- 8 week hybrid program
- Participants from Columbia, Yale, Cornell
- Topics included translational medicine, statistical considerations, the informed consent process, regulatory framework, adverse event reporting, industry partnerships, patient and community advocacy, implicit bias, and overcoming barriers
- Sessions included lectures, workshops, interactive case studies, and panel discussions
- Feedback was elicited with anonymous surveys at the beginning, midpoint, and conclusion and used to inform future iterations

OUTCOMES

- 88 total participants (38 participants attended the required five out of eight sessions across 16 departments)
- 58% were from Oncology, 16% from Medicine, 11% from Pediatrics, 9% from Psychiatry

OUTCOM

Participants

- 39% clin
- 47% stat
- 13% bei
- 32% rep research

Significant b survey):

- 81% said
- 77% rep
- respons
- 58% rep

Post-program

- 70% wo
- 60% war
- 55% wo

Demograph *Race and g *Out of the



COLUMBIA UNIVERSITY HERBERT IRVING COMPREHENSIVE CANCER CENTER


MES (Cont.)			
s were at different stages in their career: nical fellows and faculty aff		Pre	and Po
ing participants from other institutions ported no formal training in clinical trials, though 48% had som		0% —	
h experience	50	0% —	
barriers to becoming a clinical investigator (reported through the stress of the stres		0% —	
id limited opportunities for a comprehensive clinical trial trair ported time constraints due to other clinical, research and/or te	••••		
sibilities	30	0% —	
porting financial barriers	2	0% -	
am survey reports:			13%
ould like interactive workshops ant to see a library of resources ould like information session in a future iteration of our training		0%	
nic Information: gender: Self identified, adds up to >100%		0%	Lee
e 19 who answered the demographic questions			disag
			Strongly disagree
Race	Gender		
4%23% 34% 12% 23%			"I feel co
ian			LESSC
ack		•	Feedk
spanic, Latinx, or Spanish Origin	84%	•	Plan t Plan t
		•	

- Multiracial
- Middle Eastern or North African



Female Male

ost Survey Results Comparison:



ONS LEARNED/FUTURE DIRECTION

- back indicates this program addresses an unmet education need to expand the program's reach to regional academic institutions to **address regional disparities** (i.e., rural and native populations)
- Add sessions on **barriers to LGBTQ involvement** in trials and sessions on **authorship** and publication
- Collect long-term data on our participants to understand what percentage ultimately pursue a career in clinical research

-NewYork-Presbyterian